BCR-ABL fusion protein (b3a2) (920-936)

BCR-ABL fusion protein (b3a2) (920-936) is a recombinant peptide fragment derived from the breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (ABL1) fusion, specifically corresponding to the b3a2 junction region encompassing amino acids 920 to 936. This fusion protein is a hallmark molecular signature of the Philadelphia chromosome, commonly associated with chronic myeloid leukemia (CML) and certain acute lymphoblastic leukemias (ALL). The b3a2 variant represents one of the most prevalent BCR-ABL transcript types, making it a critical focus for molecular oncology and hematological research. By providing a defined segment of the fusion junction, this peptide serves as a valuable tool for investigating the molecular mechanisms underlying leukemogenesis and for developing sensitive detection methods.

Molecular diagnostics development: The b3a2 junction peptide is widely utilized as a reference standard in the design and validation of molecular assays, such as quantitative reverse transcription PCR (qRT-PCR) and digital PCR, targeting the BCR-ABL fusion transcript. Its precise sequence enables the establishment of assay specificity and sensitivity, facilitating the detection and quantification of minimal residual disease (MRD) in patient-derived samples. Researchers employ this peptide to calibrate and optimize diagnostic platforms, ensuring reliable discrimination between different BCR-ABL isoforms and enhancing the accuracy of molecular monitoring in hematological malignancies.

Antibody generation and validation: The unique amino acid sequence spanning the BCR-ABL b3a2 junction provides a highly specific antigenic epitope for the production of monoclonal and polyclonal antibodies. Such antibodies are instrumental for immunodetection applications, including western blotting, immunohistochemistry, and flow cytometry, allowing for the selective identification of leukemic cells expressing the fusion protein. The peptide fragment serves as an immunogen or as a positive control in antibody-based assays, supporting the development of robust reagents for basic research and translational studies focused on BCR-ABL-driven pathologies.

Peptide-based functional studies: Researchers leverage the b3a2 (920-936) peptide in functional assays to dissect the biochemical properties and protein-protein interactions specific to the BCR-ABL fusion region. By incorporating this defined sequence into binding studies, phosphorylation assays, or structural analyses, scientists can elucidate the molecular determinants of oncogenic signaling, kinase activity, and downstream effector recruitment. These insights contribute to a deeper understanding of leukemogenic transformation and the identification of novel therapeutic targets within the BCR-ABL signaling axis.

Assay calibration and quality control: The synthetic peptide corresponding to the BCR-ABL b3a2 junction is frequently employed as a positive control or calibration standard in research-grade analytical workflows. Its defined composition and sequence specificity make it ideal for validating assay performance, troubleshooting experimental variability, and benchmarking inter-laboratory reproducibility. By integrating this peptide into experimental protocols, laboratories can maintain rigorous quality assurance standards and ensure the reliability of molecular and immunological assays targeting BCR-ABL fusions.

Epitope mapping and neoantigen studies: The b3a2 (920-936) fusion peptide also plays a role in epitope mapping and neoantigen characterization efforts. Investigators use the peptide to define the precise regions recognized by immune receptors or antibodies, facilitating studies on immune recognition of leukemia-specific antigens. Such work is foundational for advancing the understanding of tumor immunology, informing the development of peptide-based vaccines, and guiding the rational design of targeted immunotherapeutic strategies in BCR-ABL-associated malignancies.

1. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

2. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

3. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

4. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

5. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum